Obseva shows why red flags are worth heeding

Obseva trailed the results from its second pivotal uterine fibroid study a week ago, and then failed to include crucial data in the press release, forcing investors to wait for a conference call for the big reveal. Those cynical about such tactics were proved correct: linzagolix’s profile versus the competition now looks even more questionable than before.